Skip to content

Research at St Andrews

Improved power for TB phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods

Research output: Research - peer-reviewArticle

DOI

Open Access permissions

Open

Abstract

Background: The demand for new anti-TB drugs is high, but development programmes are long and costly. Consequently there is a need for new strategies capable of accelerating this process.
Objectives: To explore the power to find statistically significant drug effects using a model-based pharmacokinetic–pharmacodynamic approach in comparison with the methods commonly used for analysing TB Phase IIa trials.
Methods: Phase IIa studies of four hypothetical anti-TB drugs (labelled A, B, C and D), each with a different mechanism of action, were simulated using the multistate TB pharmacometric (MTP) model. cfu data were simulated over 14 days for patients taking once-daily monotherapy at four different doses per drug and a reference (10 mg/kg rifampicin). The simulated data were analysed using t-test, ANOVA, mono- and bi-exponential models and a pharmacokinetic–pharmacodynamic model approach (MTP model) to establish their respective power to find a drug effect at the 5% significance level.
Results: For the pharmacokinetic–pharmacodynamic model approach, t-test, ANOVA, mono-exponential model and bi-exponential model, the sample sizes needed to achieve 90% power were: 10, 30, 75, 20 and 30 (drug A); 30, 75, 245, 75 and 105 (drug B); 70, >1250, 315, >1250 and >1250 (drug C); and 30, 110, 710, 170 and 185 (drug D), respectively.
Conclusions: A model-based design and analysis using a pharmacokinetic–pharmacodynamic approach can reduce the number of patients required to determine a drug effect at least 2-fold compared with current methodologies. This could significantly accelerate early-phase TB drug development.
Close

Details

Original languageEnglish
Pages (from-to)2311-2319
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume72
Issue number8
Early online date16 May 2017
DOIs
StatePublished - 1 Aug 2017

    Research areas

  • Tuberculosis, Clinical trials, Pharmacology, Mathematical modelling, Drug development

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. The impact of repeated NALC/NaOH- decontamination on the performance of Xpert MTB/RIF assay

    Rachow, A., Saathoff, E., Mtafya, B., Mapamba, D., Mangu, C., Rojas-Ponce, G., Ntinginya, N. E., Boeree, M., Heinrich, N., Gillespie, S. H., Hoelscher, M. & on behalf of the PanACEA-Consortium 4 Apr 2018 In : Tuberculosis. In press

    Research output: Research - peer-reviewArticle

  2. A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses

    Svensson, R. J., Aarnoutse, R. E., Diacon, A. H., Dawson, R., Gillespie, S. H., Boeree, M. J. & Simonsson, U. S. H. Apr 2018 In : Clinical Pharmacology & Therapeutics. 103, p. 674-683 10 p.

    Research output: Research - peer-reviewArticle

  3. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis

    Fregonese, F. , Ahuja, S. D. , Akkerman, O. W. , Arakaki-Sanchez, D. , Ayakaka, I. , Baghaei, P. , Bang, D. , Bastos, M. , Benedetti, A. , Bonnet, M. , Cattamanchi, A. , Cegielski, P. , Chien, J-Y. , Cox, H. , Dedicoat, M. , Erkens, C. , Escalante, P. , Falzon, D. , Garcia-Prats, A. J. , Gegia, M. & 38 others Gillespie, S. H., Glynn, J. R., Goldberg, S., Griffith, D., Jacobson, K. R., Johnston, J. C., Jones-López, E. C., Khan, A., Koh, W-J., Kritski, A., Lan, Z. Y., Lee, J. H., Li, P. Z., Maciel, E. L., Galliez, R. M., Merle, C. S. C., Munang, M., Narendran, G., Nguyen, V. N., Nunn, A., Ohkado, A., Park, J. S., Phillips, P. P. J., Ponnuraja, C., Reves, R., Romanowski, K., Seung, K., Schaaf, H. S., Skrahina, A., Soolingen, D. V., Tabarsi, P., Trajman, A., Trieu, L., Banurekha, V. V., Viiklepp, P., Wang, J-Y., Yoshiyama, T. & Menzies, D. Apr 2018 In : The Lancet Respiratory Medicine. 6, 4, p. 265-275 11 p.

    Research output: Research - peer-reviewArticle

  4. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Wills, G. H., Crook, A. M., Dawson, R., Diacon, A. H., Louw, C. E., McHugh, T. D., Mendel, C., Meredith, S., Mohapi, L., Murphy, M. E., Murray, S., Murthy, S., Nunn, A. J., Phillips, P. P. J., Singh, K., Spigelman, M. & Gillespie, S. H. 28 Mar 2018 In : BMC Medicine. 16, 10 p., 46

    Research output: Research - peer-reviewArticle

Related by journal

  1. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation

    Millard, J., Pertinez, H., Bonnett, L., Model, E. M., Dartois, V., Johnson, J. L., Caws, M., Tiberi, S., Bolhuis, M., Alffenaar, J-W. C., Davies, G. & Sloan, D. J. 23 Mar 2018 In : Journal of Antimicrobial Chemotherapy. Advance Article, 8 p.

    Research output: Research - peer-reviewArticle

  2. Has primary care antimicrobial use really been increasing? Comparison of changes in different prescribing measures for a complete geographic population 1995–2014

    Neilly, M. D. J., Guthrie, B., Hernandez Santiago, V., Vadiveloo, T., Donnan, P. T. & Marwick, C. A. 1 Oct 2017 In : Journal of Antimicrobial Chemotherapy. 72, 10, p. 2921-2930 10 p.

    Research output: Research - peer-reviewArticle

  3. ST3268: a geographically widespread primate MRSA clone

    Hsu, L-Y., Holden, M. T. G., Koh, T. H., Pettigrew, K. A., Cao, D., Hon, P. Y., Sergio, D. M., Pena, E. & Ogden, B. E. 1 Aug 2017 In : Journal of Antimicrobial Chemotherapy. 72, 8, p. 2401-2403 2 p.

    Research output: Research - peer-reviewLetter

  4. Time series analysis of the impact of an intervention in Tayside, Scotland to reduce primary care broad-spectrum antimicrobial use

    Hernandez-Santiago, V., Marwick, C. A., Patton, A., Davey, P. G., Donnan, P. T. & Guthrie, B. 1 Aug 2015 In : Journal of Antimicrobial Chemotherapy. 70, 8, p. 2397-2404 8 p., dkv095

    Research output: Research - peer-reviewArticle

ID: 250039676